Official Title: “SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects”

The purpose of this study is to obtain data of the coadministration of ezetimibe and rosuvastatin to support the concomitant use of these two drugs in patients requiring additional cholesterol-lowering management. Treatment is administered for 14 days.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study

Study Primary Completion Date: May 2003

Intervention(s) in this Clinical Trial

• Drug: Ezetimibe + Rosuvastatin
  • oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
• Drug: Rosuvastatin
  • oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
• Drug: Placebo
  • oral tablets; two ezetimibe placebo once daily for 14 days
• Drug: Ezetimibe
  • oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Ezetimibe + Rosuvastatin
• Active Comparator: Ezetimibe
• Active Comparator: Rosuvastatin
• Placebo Comparator: Placebo

Primary Measures

• Percent change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides.
  • Time Frame: Day 15
    Safety Issue?: No
• Safety: adverse events, laboratory test results, physical examination, vital signs.
  • Time Frame: Throughout study
    Safety Issue?: Yes

Secondary Measures

• Evaluate potential for PK interaction between ezetimibe and rosuvastatin as indicated by Cmax and AUC.
  • Time Frame: Day 14
    Safety Issue?: No

Inclusion Criteria:

• Males and females between the ages of 18 and 55 years inclusive, having a Body Mass
• Index (BMI) between 19-31 inclusive. BMI=weight (kg)/height (m^2).
• Subjects must have untreated hypercholesterolemia with a directly measured fasting
• LDL-C >=130 mg/dL (3.37 mmol/L) at Screening and on Day -1.
• Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with the study evaluations.
• Subjects must have a normal or clinically acceptable physical exam and ECG (12-lead recorded at 25 mm/s and reporting heart rate and PR, QRS, QT, and QTc intervals).
• Subjects' clinical laboratory tests (CBC, blood chemistries, and urinalysis) must be within normal limits or clinically acceptable to the investigator/ sponsor.
• Screen for drugs with high potential for abuse must be negative.
• Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules.
• Subjects must be willing to comply with the NCEP Step 1 diet for at least one week as outpatients, and during the inpatient treatment period.
• Female subjects must be of nonchildbearing potential (ie, surgically sterilized or postmenopausal for at least one year), or, if they are of childbearing potential they must be using a medically accepted method of birth control prior to Screening and agree to continue its use during the study or be surgically sterilized (eg, hysterectomy or tubal ligation). Females of childbearing potential should be counseled in the appropriate use of birth control while in this study. Females who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
• Female subjects must have a negative serum pregnancy test (beta-hCG) at Screening.

Exclusion Criteria:

• Female subjects who are pregnant, intend to become pregnant, or are nursing.
• Subjects who previously received or were treated with ezetimibe (SCH 58235) or rosuvastatin.
• Subjects who previously received or were treated with lipid lowering drugs (including
• OTC fish oil and phytosterols) within 6 weeks of Visit 1.
• Any subject who does not comply with the requirement that he/she should not have used any prescription or over-the-counter drugs (except for aspirin or acetaminophen
• [paracetamol]) within two weeks prior to study drug administration nor alcohol within 48 hours prior to study drug administration.
• Subjects who have used any investigational drugs or donated blood within 30 days of study entry.
• Subjects with pre-existing gallbladder disease or a history of liver function test abnormalities.
• Subjects who smoke more than ten cigarettes or equivalent tobacco use per day.
• Subjects who have a clinically significant allergy or intolerance to foods or drugs, especially to any component of ezetimibe (ZETIA™/EZETROL™) or rosuvastatin (CRESTOR™).
• Subjects who are positive for HIV antibodies, hepatitis B surface antigen or hepatitis
• C antibody.
• Subjects with a history of mental instability or who have been or are being treated for mood disorders.
• Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
• Subjects who are participating in any other clinical study.
• Subjects who are part of the staff personnel directly involved with this study.
• Subjects who are a family member of the investigational study staff.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 55 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Schering-Plough

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00651144

Study ID Number: P03317

ClinicalTrials.gov Identifier: NCT00651144

Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)